Advanced search
Publication Cover
Immunotherapy Volume 3, 2011 - Issue 2
Submit an article Journal homepage
85
Views
0
CrossRef citations to date
0
Altmetric
Drug Evaluation

Abagovomab: An Anti-Idiotypic CA-125 Targeted Immunotherapeutic Agent for Ovarian Cancer

Rachel N Grisham1 Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY10065, USA
,
Jonathan Berek2 Women‘s Cancer Center, Department of Obstetrics & Gynecology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA94305, USA
,
Jacobus Pfisterer3 Department of Gynecology, Staedtisches Klinikum Solingen, Gotenstr. 1, 42653Solingen, Germany
&
Paul Sabbatini1 Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY10065, USACorrespondence[email protected]
Pages 153-162 | Published online: 15 Feb 2011

Bibliography

  • Jemal A, Siegel R, Xu J, Ward E: Cancer Statistics, 2010. CA Cancer J. Clin.60(5) , 277–300 (2010).
  • Markman M , MarkmanJ, WebsterK et al.: Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.J. Clin. Oncol.22(15) , 3120–3125 (2004).
  • Armstrong DK , BundyB, WenzelL et al.; Gynecologic Oncology Group: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med.354(1) , 34–43 (2006).
  • Ozols RF , BundyBN, GreerBE et al.: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.J. Clin. Oncol.21(17) , 3194–3200 (2003).
  • Markman M , LiuPY, WilczynskiS et al.; Southwest Oncology Group; Gynecologic Oncology Group: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J. Clin. Oncol.21(13) , 2460–2465 (2003).
  • Markman M , LiuPY, MoonJ et al.: Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group Phase III trial.Gynecol. Oncol.114(2) , 195–198 (2009).
  • Hall GD , BrownJM, ColemanRE et al.: Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire Gynaecology Group randomised Phase III study.Br. J. Cancer91(4) , 621–626 (2004).
  • Alberts DS , HanniganEV, LiuPY et al.: Randomized trial of adjuvant intraperitoneal α-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: an intergroup study.Gynecol. Oncol.100(1) , 133–138 (2006).
  • Schilder RJ , BradyMF, SpriggsD, SheaT: Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a Gynecologic Oncology Group study.Gynecol. Oncol.88(1) , 3–8 (2003).
  • Lambert HE , RustinGJ, GregoryWM, NelstropAE: A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group study.J. Clin. Oncol.11(3) , 440–448 (1993).
  • Sorbe B : Consolidation treatment of advanced ovarian carcinoma with radiotherapy after induction chemotherapy.Int. J. Gynecol. Cancer13(Suppl. 2) , 192–195 (2003).
  • Varia MA , StehmanFB, BundyBN et al.; Gynecologic Oncology Group: Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J. Clin. Oncol.21(15) , 2849–2855 (2003).
  • Nicoletto MO , TumoloS, FalciC et al.: A randomized study of epithelial ovarian cancer: is chemotherapy useful after complete remission?Int. J. Med. Sci.1(2) , 116–125 (2004).
  • De Placido S , ScambiaG, Di Vagno G, et al.: Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J. Clin. Oncol.22(13) , 2635–2642 (2004).
  • Berek JS , TaylorPT, GordonA et al.: Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer.J. Clin. Oncol.22(17) , 3507–3516 (2004).
  • Verheijen RH , MassugerLF, BenignoBB et al.: Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission.J. Clin. Oncol.24(4) , 571–578 (2006).
  • Sabbatini P : Consolidation therapy in ovarian cancer: a clinical update.Int. J. Gynecol. Cancer19(Suppl. 2) , S35–S39 (2009).
  • Dizon DS , HensleyML, PoynorEA et al.: Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarianCancer J. Clin. Oncol.20(5) , 1238–1247 (2002).
  • Muggia FM , BralyPS, BradyMF et al.: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study.J. Clin. Oncol.18(1) , 106–115 (2000).
  • Slavin S , AckersteinA, OrR et al.: Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a Phase I study.Cancer Immunol. Immunother.59(10) , 1511–1519 (2010).
  • Perez SA , von Hofe E, Kallinteris NL et al.: A new era in anticancer peptide vaccines. Cancer116(9) , 2071–2080 (2010).
  • Burger RA , BradyMF, BookmanMA et al.: Phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer: a Gynecology Oncology Group Study.J. Clin. Oncol.28 , Abstract LBA1 (2010).
  • Weiner LM , DhodapkarMV, FerroneS: Monoclonal antibodies for cancer immunotherapy.Lancet.373(9668) , 1033–1040 (2009).
  • Smyth MJ , DunnGP, SchreiberRD: Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.Adv. Immunol.90 , 1–50 (2006).
  • Zitvogel L , TesniereA, KroemerG: Cancer despite immunosurveillance: immunoselection and immunosubversion.Nat. Rev. Immunol.6(10) , 715–727 (2006).
  • Bhattacharya-Chatterjee M , ChatterjeeS, FoonK: Anti-idiotype antibody vaccine therapy forCancer Expert Opin. Biol. Ther.2(8) , 869–881 (2002).
  • Juretzka MM , BarakatRR, ChiDS et al.: CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.Gynecol. Oncol.104(1) , 176–180 (2007).
  • Berek JS , TaylorPT, NicodemusCF: CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarianCancer J. Immunother.31(2) , 207–214 (2008).
  • Duffy MJ , BonfrerJM, KulpaJ et al.: CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use.Int. J. Gynecol. Cancer15(5) , 679–691 (2005).
  • Bafna S , KaurS, BatraSK: Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells.Oncogene29(20) , 2893–2904 (2010).
  • Gubbels JA , BelisleJ, OndaM et al.: Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.Mol. Cancer5(1) , 50 (2006).
  • Leffers N , FehrmannRS, GoodenMJ et al.: Identification of genes and pathways associated with cytotoxic T-lymphocyte infiltration of serous ovarian cancer.Br. J. Cancer103(5) , 685–692 (2010).
  • O‘Brien TJ , BeardJB, UnderwoodLJ, DennisRA, SantinAD, YorkL: The CA125 gene: an extracellular superstructure dominated by repeat sequences.Tumour Biol.22(6) , 348–366 (2001).
  • Yin BW , DnistrianA, LloydKO: Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene.Int. J. Cancer98(5) , 737–740 (2002).
  • Lloyd KO , YinBW, KudryashovV: Isolation and characterization of ovarian cancer antigen CA-125 using a new monoclonal antibody (VK-8): identification as a mucin-type molecule.Int. J. Cancer71(5) , 842–850 (1997).
  • Yin BW , LloydKO: Molecular cloning of the CA-125 ovarian cancer antigen: identification as a new mucin, MUC16.J. Biol. Chem.276(29) , 27371–27375 (2001).
  • Noujaim AA , SchultesBC, BaumRP, MadiyalakanR: Induction of CA-125-specific B- and T-cell responses in patients injected with MAb-B43.13 – evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo.Cancer Biother. Radiopharm.16(3) , 187–203 (2001).
  • Berek JS , SchultesBC, NicodemusCF: Biologic and immunologic therapies for ovarian cancer.J. Clin. Oncol.21(Suppl. 10) , 168–174 (2003).
  • Baum RP , NoujaimAA, NanciA et al.: Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13.Hybridoma12(5) , 583–589 (1993).
  • Ehlen TG , HoskinsPJ, MillerD et al.: A pilot Phase II study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer.Int. J. Gynecol. Cancer15(6) , 1023–1034 (2005).
  • Möbus VJ , BaumRP, BolleM et al.: Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer.Am. J. Obstet. Gynecol.189(1) , 28–36 (2003).
  • Berek J , TaylorP, McGuireW, SmithLM, SchultesB, NicodemusCF: Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer.J. Clin. Oncol.27(3) , 418–425 (2009).
  • Jerne NK : Towards a network theory of the immune system.Ann. Immunol.125 , 373–389 (1974).
  • Herlyn D , RossAH, KoprowskiH: Anti-idiotypic antibodies bear the internal image of a human tumor antigen.Science232(4746) , 100–102 (1986).
  • Herlyn D , HarrisD, ZaloudikJ et al.: Immunomodulatory activity of monoclonal anti-idiotypic antibody to anti-colorectal carcinoma antibody CO17–1A in animals and patients.J. Immunother. Emphasis Tumor Immunol.15(4) , 303–311 (1994).
  • Raychaudhuri S , KangCY, KaveriSV, Kieber-EmmonsT, KöhlerH: Tumor idiotype vaccines. VII. Analysis and correlation of structural, idiotypic and biologic properties of protective and nonprotective Ab2.J. Immunol.145(2) , 760–767 (1990).
  • Ruiz PJ , WolkowiczR, WaismanA et al.: Idiotypic immunization induces immunity to mutated p53 and tumor rejection.Nat. Med.4(6) , 710–712 (1998).
  • Yáñez R , BarriosY, RuizE, CabreraR, Díaz-EspadaF: Anti-idiotypic immunotherapy in follicular lymphoma patients: results of a long follow-up study.J. Immunother.31(3) , 310–312 (2008).
  • Neninger E , DíazRM, de la Torre A et al.: Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small-cell-lung cancer: report of a Phase I trial. Cancer Biol. Ther.6(2) , 145–150 (2007).
  • Saleh MN , LoBuglioAF, WheelerRH et al.: A Phase II trial of murine monoclonal antibody 17–1A and interferon-γ: clinical and immunological data.Cancer Immunol. Immunother.32(3) , 185–190 (1990).
  • Posner MC , NiedzwieckiD, VenookAP et al.: A Phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: Cancer and Leukemia Group B study 89903.Ann. Surg. Oncol.15(1) , 158–164 (2008).
  • Foon KA , Bhattacharya-ChatterjeeM: Are solid tumor anti-idiotype vaccines ready for prime time? Commentary re: Wagner U et al.: Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment.Clin. Cancer Res.7 , 1154–1162 (2001). Clin. Cancer Res.7(5) , 1112–1115 (2001).
  • Schlebusch H, Wagner U, Grünn U, Schultes B: A monoclonal anti-idiotypic antibody ACA 125 mimicking the tumor-associated antigen CA125 for immunotherapy of ovarian cancer Hybridoma14(2) , 167–174 (1995).
  • Wagner U , KöhlerS, ReinartzS et al.: Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA 125: immune responses and survival in palliative treatment. See: The biology behind: Foon KA & Bhattacharya-Chatterjee M, Are solid tumor anti-idiotype vaccines ready for prime time?Clin. Cancer Res.7 , 1112–1115 (2001). Clin. Cancer Res.7(5) , 1154–1162 (2001).
  • Reinartz S , KöhlerS, SchlebuschH et al.: Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (Phase Ib/II).Clin. Cancer Res.10(5) , 1580–1587 (2004).
  • Pfisterer J , du Bois A, Sehouli J et al.: The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A Phase I trial of the AGO-OVAR. Ann. Oncol.17(10) , 1568–1577 (2006).
  • Sabbatini P , SpriggsDR: Consolidation for ovarian cancer in remission.J. Clin. Oncol.24(4) , 537–539 (2006).
  • Sabbatini P , BerekJS, CasadoA et al.: Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response (CR) post-first-line chemotherapy (FLCT): preliminary results of the randomized, double-blind, placebo-controlled, multicenter MIMOSA trial.J. Clin. Oncol.28 , Abstract 5036 (2010).
  • Sabbatini P , DupontJ, AghajanianC et al.: Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.Clin. Cancer Res.12(18) , 5503–5510 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.